(Q36327078)

13 August 2017

1 reference

title

Advances in the management of myeloma bone disease (English)

1 reference

13 August 2017

Claire M Shipman

1

1 reference

13 August 2017

Babatunde O Oyajobi

series ordinal

2

1 reference

13 August 2017

Gregory R Mundy

series ordinal

3

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

2781-2791

1 reference

13 August 2017

16

1 reference

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Bisphosphonates: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

WNT and beta-catenin signalling: diseases and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Not just research tools--proteasome inhibitors offer therapeutic promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.16.2781

10.1517/14656566.6.16.2781

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference